使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Ladies and gentlemen, thank you for standing by and welcome to the Intuitive Surgical Q3 2013 earnings release conference call.
各位女士、先生,感謝您稍候並歡迎參加 Intuitive Surgical 2013 年第三季財報發布電話會議。
At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. (Operator Instructions). Also as a reminder, today's teleconference is being recorded.
此刻所有與會者皆處於僅收聽模式。稍後我們將進行問答環節,屆時會提供相關指示。(接線員指示)。另外提醒您,今天的電話會議將被錄音。
At this time, I will turn the conference call over to your host, Senior Director of Finance for Intuitive Surgical, Mr. Calvin Darling. Please go ahead sir.
現在我將把電話會議交給本次主持人——Intuitive Surgical 財務資深總監 Calvin Darling 先生。先生,請開始。
Calvin Darling - Senior Director of Finance
Calvin Darling - Senior Director of Finance
Thank you. Good afternoon and welcome to Intuitive Surgical's third-quarter earnings conference call. With me today we have Gary Guthart, our President and CEO, Marshall Mohr, our Chief Financial Officer, and Aleks Cukic, our Vice President of Strategic Planning.
謝謝。各位下午好,歡迎參加 Intuitive Surgical 第三季財報電話會議。今天與我一同出席的有:我們的總裁暨執行長 Gary Guthart、財務長 Marshall Mohr,以及策略規劃副總裁 Aleks Cukic。
Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the Company's Securities and Exchange Commission filings included in our most recent Form 10-K filed on February 4, 2013, and our Form 10-Q filed on July 22, 2013. These filings can be found through our website, or at the SEC's EDGAR database. Prospective investors are cautioned not to place undue reliance on such forward-looking statements.
在開始之前,我想提醒各位,今天電話會議中提及的評論可能被視為包含前瞻性陳述。由於某些風險與不確定性,實際結果可能與明示或暗示的內容存在重大差異。這些風險與不確定性已在公司向美國證券交易委員會(SEC)提交的文件中詳述,包括我們於 2013 年 2 月 4 日提交的最新 Form 10-K,以及於 2013 年 7 月 22 日提交的 Form 10-Q。這些文件可透過我們的網站或 SEC 的 EDGAR 資料庫查閱。提醒潛在投資人勿過度依賴此類前瞻性陳述。
Please note that this conference call will be available for audio replay on our website at IntuitiveSurgical.com on the "Audio Archive" section under our Investor Relations page. In addition, today's press release has been posted to our website.
請注意,本次電話會議將於 IntuitiveSurgical.com 我們投資人關係頁面下的「Audio Archive」區提供音訊重播。此外,今天的新聞稿也已發布於我們的網站。
Today's format will consist of providing you with highlights of our third-quarter results as described in our press release announced earlier today, followed by a question-and-answer session. Gary will present the quarter's business and operational highlights. Marshall will provide a review of our third-quarter financial results. Aleks will discuss marketing and clinical highlights. Then I will provide an update to our financial forecast for 2013. And finally, we will host a question-and-answer session.
今天的流程將先為各位提供我們第三季業績重點(如今日稍早發布的新聞稿所述),接著進行問答環節。Gary 將說明本季的業務與營運重點。Marshall 將回顧我們第三季的財務結果。Aleks 將討論行銷與臨床重點。接著我將更新我們對 2013 年的財務預測。最後,我們將進行問答環節。
With that, I'll turn it over to Gary.
接下來交給 Gary。
Gary Guthart - President, CEO, Director
Gary Guthart - President, CEO, Director
Thank you for joining us today. This quarter, we continued to see significant pressure on our US business. Trends that started in the first half of the year in gynecology have continued. On the procedure side, underlying causes for slowing growth include weaker overall gynecologic admissions which is pressuring surgical volume.
感謝各位今天加入我們。本季我們持續看到美國業務面臨顯著壓力。今年上半年在婦科領域開始出現的趨勢仍在延續。在手術量方面,成長放緩的根本原因包括整體婦科住院人次走弱,進而壓抑手術量。
There are also lingering ill-founded concerns regarding the benefits of da Vinci surgery compared to the available surgical alternatives. Since we are a significant share of hysterectomy, our growth rate is sensitive to these issues. This slowed growth has resulted in capacity in our US installed base, combined with changes in hospital capital spending associated with the implementation of the Affordable Care Act, US capital sales fell substantially compared to prior year.
此外,市場上仍存在一些缺乏根據的疑慮,認為達文西手術相較於現有手術替代方案的效益不明顯。由於我們在子宮切除術中占有相當高的比重,我們的成長率對這些議題相當敏感。成長放緩導致我們在美國已安裝機台基礎出現產能餘裕,再加上《平價醫療法案》(Affordable Care Act)實施所帶來的醫院資本支出變化,使得美國資本設備銷售較去年同期大幅下滑。
Overall procedure trends in the quarter were stable, rising 16% over prior year. In the United States, general surgery was our fastest-growing segment led by Single-Site cholecystectomy and followed by growth in colon and rectal resections. Our gynecology business still grew year-over-year, but at a slower pace than prior quarters, and urologic procedures in the US were stable compared to prior year.
整體而言,本季手術量趨勢穩定,較去年同期成長 16%。在美國,一般外科是我們成長最快的領域,主要由 Single-Site 膽囊切除術帶動,其次為結腸與直腸切除術的成長。我們的婦科業務仍較去年同期成長,但增速低於前幾季;而美國泌尿科手術量則與去年同期持平。
In Europe, we are continuing our investments in market access and clinical research. We are seeing early positive results in HTA and reimbursement analyses as a consequence of these efforts. Year-over-year procedure growth accelerated, led by urology and other growth in malignant gynecology. Growth was strongest in the UK, France, Italy, and the Nordic countries.
在歐洲,我們持續投資於市場准入與臨床研究。在這些努力之下,我們在健康技術評估(HTA)與給付(reimbursement)分析方面已看到初步的正面成果。手術量年增率加速,主要由泌尿科帶動,並伴隨惡性婦科等其他領域的成長。成長最強勁的市場為英國、法國、義大利以及北歐國家。
Procedure growth in Asia with solid off a small base led by growth in urology and general surgery.
亞洲的手術量在較小的基期上呈現穩健成長,主要由泌尿科與一般外科帶動。
With regard to resolution of our FDA warning letter, we are making good progress in addressing the elements of the letter and the Form 483 that preceded it. As part of our work in responding to the letter, we expect to file corrections and updates to our labeling and to file documentation for some past field actions. These activities will be documented on the FDA's website over the next several weeks.
關於我們 FDA 警告信的結案處理,我們在回應該信函及其之前的 Form 483 各項要素方面進展良好。作為回應信函工作的一部分,我們預期將提交標示(labeling)的更正與更新,並就部分過往的現場行動(field actions)補提文件。未來數週內,這些活動將在 FDA 網站上留有紀錄。
Turning to our operating performance for the third quarter, procedures grew approximately 16% over the third quarter of 2012. We sold 101 da Vinci surgical systems, down from 155 during the third quarter of last year.
回到第三季的營運表現,手術量較 2012 年第三季約成長 16%。我們售出 101 套達文西手術系統,低於去年第三季的 155 套。
Total revenue was $499 million, down 7% from last year. Instrument and accessory revenue was $239 million, up 10% over Q3 2012. Total recurring revenue grew to $341 million, up 11% from prior year and comprising 68% of total revenue. Net income was $157 million, down 14% over last year. And we generated an operating profit of $225 million before non-cash stock option expense, down 13% from the third quarter of last year and representing 45% of Q3 revenue.
總營收為 4.99 億美元,較去年下降 7%。器械與配件營收為 2.39 億美元,較 2012 年第三季成長 10%。經常性收入總額成長至 3.41 億美元,較去年成長 11%,占總營收的 68%。淨利為 1.57 億美元,較去年下降 14%。在扣除非現金股票選擇權費用前,我們的營業利益為 2.25 億美元,較去年第三季下降 13%,相當於第三季營收的 45%。
We ended the quarter with $2.532 billion in cash and investments, down $495 million from last quarter. In the quarter, we generated $204 million in gross cash flow from operations and we repurchased $694 million of our stock.
本季末我們持有的現金與投資為 25.32 億美元,較上季減少 4.95 億美元。本季我們自營運產生 2.04 億美元的毛現金流,並回購了 6.94 億美元的公司股票。
Our new products continue to gain acceptance with customers. We expanded our stapling rollout at a measured pace through the first three quarters of this year. Surgeons' clinical feedback on the stapler has been strong and our stapling operations depth has increased substantially. We will accelerate the stapling launch in Q4 and beyond.
我們的新產品持續獲得客戶接受。今年前三季我們以審慎的步調擴大縫合器(stapling)的推廣。外科醫師對該縫合器的臨床回饋相當正面,我們在縫合相關營運的深度也大幅提升。我們將在第四季及之後加速縫合器的上市推進。
This quarter, we received FDA clearance for an expanded indication of our Firefly system to include biliary imaging in combination with normal white light imaging during cholecystectomy. This is another step in providing surgeons with imaging capability that enables them to see anatomical structure beyond what can be seen with the naked eye.
本季我們取得 FDA 核准,擴大 Firefly 系統的適應症,納入於膽囊切除術中結合一般白光影像進行膽道影像(biliary imaging)。這是我們為外科醫師提供影像能力的另一個進展,使其能看見超出肉眼可見範圍的解剖結構。
Our Single-Site product line continues to perform well. Single-Site cholecystectomy is moving out of early adopting centers into the broader clinical practice. Single-Site for hysterectomy progressed during the quarter while on limited release. As part of this limited release, customers have requested an additional instrument, a wrist needle driver to complement the product line. We have designed it, are testing it and plan to submit an application in early Q1 to the US FDA for 510(k) clearance. We believe the addition of a wrist to Single-Site instruments will optimize the procedure for surgeons who expect EndoWrist functionality. Our Single-Site products are well positioned to deliver increased patient satisfaction with reasonable economics for single incision surgery.
我們的 Single-Site 產品線持續表現良好。Single-Site 膽囊切除術正從早期採用中心擴展至更廣泛的臨床實務。Single-Site 子宮切除術在本季於有限上市(limited release)期間持續推進。在此有限上市過程中,客戶要求新增一項器械——腕式持針器(wrist needle driver)以補強產品線。我們已完成設計並正在測試,並計畫於第一季初向美國 FDA 提交 510(k) 許可申請。我們相信,為 Single-Site 器械加入腕部功能,將可為期待 EndoWrist 功能的外科醫師優化手術流程。我們的 Single-Site 產品具備良好定位,可在單一切口手術中,以合理的經濟性提升病患滿意度。
We have great confidence in the safety, efficacy and cost effectiveness of our products and we remain deeply positive on the value da Vinci brings to surgery now and in the future. The benefit da Vinci brings as an alternative to open surgery has been demonstrated in hundreds of independent peer reviewed clinical papers. Increasingly, well-designed cost studies demonstrate that upfront and operating investments in da Vinci surgery are offset by downstream savings resulted from fewer complications, readmissions and length of stay.
我們對產品的安全性、有效性與成本效益深具信心,並持續高度看好達文西在當前及未來為外科手術帶來的價值。達文西作為傳統開腹手術替代方案所帶來的效益,已在數百篇獨立、同儕審查的臨床論文中獲得證實。越來越多設計完善的成本研究顯示,對達文西手術的前期與手術中投資,可由後端節省所抵銷,這些節省來自較少的併發症、再入院以及住院天數縮短。
We have recently updated IntuitiveSurgical.com with links to high level of evidence clinical data and adverse event data, and in the next few days we'll add abstracts of well-designed peer-reviewed cost studies comparing da Vinci surgery to open surgery alternatives. We encourage a full and careful examination of the literature by anyone interested in the facts about da Vinci use.
我們最近已更新 IntuitiveSurgical.com,新增連結至高層級證據的臨床資料與不良事件資料;並且在接下來幾天內,我們將加入經良好設計且同儕審查的成本研究摘要,這些研究比較達文西手術與傳統開放手術替代方案。我們鼓勵任何對達文西使用相關事實感興趣的人,完整且審慎地檢視相關文獻。
In summary, we continue to see substantial long-term opportunity to fundamentally improve surgery using our technologies. and we are focused on the following -- first, educating the surgical community on the facts about da Vinci surgery, including its safety, efficacy and cost effectiveness; next, building da Vinci capability and supporting its use in general surgery; extending the benefits of minimally invasive surgery using da Vinci in gynecology and urology worldwide; and disciplined execution in expanding our stapling and Single-Site adoption.
總結而言,我們持續看到運用我們的技術從根本上改善外科手術的重大長期機會。我們聚焦於以下幾點——第一,向外科社群宣導達文西手術的事實,包括其安全性、有效性與成本效益;其次,建立達文西在一般外科的能力並支持其使用;在全球於婦科與泌尿科擴大使用達文西以延伸微創手術的效益;以及以嚴謹的執行力推動我們的縫合器與 Single-Site 的採用擴張。
I'll now pass the time over to Marshall, our Chief Financial Officer.
接下來我把時間交給我們的財務長 Marshall。
Marshall Mohr - SVP, CFO
Marshall Mohr - SVP, CFO
Thank you Gary. Our third-quarter 2013 revenue was $499 million, down 7% compared with $538 million for the third quarter of 2012, and down 14% from last quarter. Third-quarter revenues per product category were as follows. Third-quarter Instrument and Accessory revenue was $239 million, up 10% compared with $218 million for the third quarter of 2012 and down 10% compared with the second quarter of 2013. The year-over-year increase in Instrument and Accessory revenue was driven by procedure growth of approximately 16%. Sales of new products, including Single-Site, Vessel Sealer and Firefly, partially offset by lower Instrument and Accessory stocking orders associated with fewer system sales, and the timing of customer orders. The sequential decrease in Instrument and Accessory revenue was driven by lower Instrument and Accessory stocking orders and the timing of customer orders.
謝謝你,Gary。我們2013年第三季營收為4.99億美元,較2012年第三季的5.38億美元下降7%,較上一季下降14%。第三季各產品類別營收如下。第三季器械與配件營收為2.39億美元,較2012年第三季的2.18億美元成長10%,較2013年第二季下降10%。器械與配件營收的年增主要由約16%的手術量成長所帶動。新產品銷售(包括 Single-Site、Vessel Sealer 與 Firefly)部分抵銷了因系統銷售較少而導致的器械與配件初始備貨訂單下降,以及客戶下單時點的影響。器械與配件營收的季減主要由器械與配件初始備貨訂單較少以及客戶下單時點所致。
The 16% increase in da Vinci procedures for the quarter reflected growth in general surgery and gynecology procedures in the US, and urology procedures outside of the US. The lower third-quarter growth rate reflects slower growth in US benign gynecologic procedures and flat US DVP volumes. Factors affecting US benign gynecologic procedures include reduced hospital admissions, a trend by payors toward encouraging conservative disease management and treatment in outpatient settings, and negative media reports.
本季達文西手術量成長16%,反映美國一般外科與婦科手術的成長,以及美國以外地區泌尿科手術的成長。第三季較低的成長率反映美國良性婦科手術成長放緩,以及美國 DVP 量持平。影響美國良性婦科手術的因素包括住院人次減少、付款方趨勢轉向鼓勵保守性疾病管理與門診治療,以及負面媒體報導。
Instrument and Accessory revenue realized per procedure, including initial stocking orders, was approximately $1860 per procedure compared to $1980 per procedure in the third quarter of 2012, and $2020 last quarter. Our third-quarter 2013 revenue per procedure reflected fewer stocking orders associated with fewer system sales and the timing of customer orders.
每例手術實現的器械與配件營收(包含初始備貨訂單)約為每例1,860美元,相較於2012年第三季每例1,980美元,以及上一季每例2,020美元。我們2013年第三季每例手術營收反映因系統銷售較少而導致的備貨訂單減少,以及客戶下單時點的影響。
Third-quarter 2013 systems revenue of $159 million decreased 32% compared with $232 million for the third quarter of 2012 and decreased 27% compared with $216 million last quarter. Overall, we sold 101 systems in the third quarter of 2013 compared with 155 systems last year and 143 systems last quarter. We sold 65 systems into the US market in the third quarter of 2013 compared with 114 systems last year and 90 systems last quarter. The lower third-quarter 2013 US system sales reflected, among other things, the impacts of moderating growth in US benign gynecologic procedures, increased economic pressure on hospitals, uncertainty related to and spending associated with the Affordable Care Act, and negative media reports.
2013年第三季系統營收為1.59億美元,較2012年第三季的2.32億美元下降32%,較上一季的2.16億美元下降27%。整體而言,我們在2013年第三季售出101套系統,相較去年同期155套,以及上一季143套。2013年第三季我們在美國市場售出65套系統,相較去年同期114套,以及上一季90套。2013年第三季美國系統銷售較低,反映(除其他因素外)美國良性婦科手術成長趨緩的影響、醫院面臨更大的經濟壓力、與《平價醫療法案》(Affordable Care Act)相關的不確定性及支出,以及負面媒體報導。
During the third quarter of 2013, we sold 36 systems in the international market, including 17 into Europe and 13 into Japan, compared with 41 into international markets in the third quarter of 2012, which included 13 into Europe and 16 into Japan, and 53 systems in international markets in the second quarter of 2013, which included 21 into Europe and 20 into Japan.
2013年第三季,我們在國際市場售出36套系統,其中17套銷往歐洲、13套銷往日本;相較之下,2012年第三季國際市場售出41套(其中13套銷往歐洲、16套銷往日本),而2013年第二季國際市場售出53套(其中21套銷往歐洲、20套銷往日本)。
Our third-quarter average sales price per system was $1.56 million compared with $1.48 million realized in the third quarter of 2012, and $1.5 million realized last quarter. ASPs include all da Vinci models, all simulators and Firefly when configured with the system, and exclude upgrades. Our higher third-quarter 2013 ASPs were driven by a higher proportion of dual console configurations and geographic sales mix. 29 of our third-quarter 2013 systems involve trade-ins compared with 34 trade-ins last year and 43 trade-ins last quarter.
我們第三季每套系統的平均售價為156萬美元,相較於2012年第三季的148萬美元,以及上一季的150萬美元。平均售價(ASP)包含所有達文西機型、所有模擬器,以及在系統配置中包含的 Firefly,並排除升級收入。2013年第三季較高的 ASP 主要由雙主控台配置占比提高以及地理銷售組合所帶動。我們2013年第三季的系統中有29套涉及以舊換新,相較去年同期34套,以及上一季43套。
Service revenue increased to $101 million, up 16% compared with $88 million last year and up 3% compared with $98 million last quarter. The growth in service revenue was driven by a larger system installed base.
服務營收增至1.01億美元,較去年同期的8,800萬美元成長16%,較上一季的9,800萬美元成長3%。服務營收成長由更大的系統裝機基數所帶動。
International revenue results were as follows. Third-quarter revenue outside the US was $133 million, up 15% compared with revenue of $115 million in the third quarter of last year, and down 16% compared with revenue of $158 million last quarter. Our higher year-over-year international revenue was driven by higher recurring instrument, accessory, and service revenue, partially offset by lower systems sales. Our lower sequential international revenue primarily reflects summer seasonality.
國際營收結果如下。第三季美國以外營收為1.33億美元,較去年第三季的1.15億美元成長15%,較上一季的1.58億美元下降16%。國際營收的年增由較高的經常性器械、配件與服務營收所帶動,但部分被較低的系統銷售所抵銷。國際營收的季減主要反映夏季季節性因素。
Third-quarter 2013 international procedure volume was approximately 25% higher than the third quarter of 2012 and 6% lower than the second quarter of this year. The growth over the prior year reflects DVP growth in Europe and Japan. The decrease compared to last quarter reflects summer seasonality patterns in Europe.
2013年第三季國際手術量較2012年第三季約高出25%,較今年第二季低6%。相較前一年之成長反映歐洲與日本的 DVP 成長。相較上一季之下降反映歐洲的夏季季節性模式。
Moving onto the remainder of the P&L, gross margin in the third quarter of 2013 was 71.5% compared with 72.5% for the third quarter of 2012 and 70% for the second quarter of 2013. Our lower margin percentage compared to the third quarter of last year resulted primarily from the impact of the medical device excise tax. Our higher gross margin percentage compared to last quarter was driven primarily by higher system ASPs.
接著看損益表其餘項目,2013年第三季毛利率為71.5%,相較2012年第三季為72.5%,2013年第二季為70%。相較去年第三季毛利率較低,主要是醫療器材消費稅(medical device excise tax)的影響。相較上一季毛利率較高,主要由較高的系統 ASP 所帶動。
Third-quarter 2013 operating expenses of $183 million were up 2% compared with last year, and down 2% compared with last quarter. Our higher year-over-year operating expense was driven by headcount additions, partially offset by lower incentive compensation and lower R&D prototype expenses. Our decrease compared to last quarter was driven by lower incentive compensation, partially offset by stock compensation expenses.
2013年第三季營業費用為1.83億美元,較去年成長2%,較上一季下降2%。營業費用年增主要由人員編制增加所致,但部分被較低的獎勵性薪酬與較低的研發原型支出所抵銷。相較上一季的下降由較低的獎勵性薪酬所帶動,但部分被股票薪酬費用所抵銷。
Third-quarter 2013 operating income was $174 million, or 35% of sales, compared with $211 million, or 39% of sales, last year and $219 million, or 38% of sales, last quarter.
2013年第三季營業利益為1.74億美元,約占銷售額的35%;相較之下,去年為2.11億美元(占銷售額39%),上一季為2.19億美元(占銷售額38%)。
Third-quarter 2013 operating income included $50 million of non-cash stock compensation expense compared with $47 million last year and $39 million last quarter. The increase in stock compensation expense relative to the prior quarter has to do with the timing of stock option grants and a related vesting period.
2013年第三季營業利益包含5,000萬美元的非現金股票薪酬費用,相較去年為4,700萬美元、上一季為3,900萬美元。相較前一季股票薪酬費用增加,與股票選擇權授予時點及相關歸屬期間的安排有關。
Our effective tax rate for the third quarter was 12% compared with 15% for the third quarter of 2012 and 28.6% last quarter. Both the third quarter of 2013 and the third quarter of 2012 tax rates benefited from the release of reserves specific to tax years where the statute of limitations have now expired. Excluding one-time benefits, our third-quarter 2013 tax provision would have been approximately $26 million higher and our third-quarter 2012 tax provision would have been approximately $35 million higher.
我們第三季有效稅率為12%,相較2012年第三季為15%,上一季為28.6%。2013年第三季與2012年第三季的稅率皆受惠於針對已逾追溯時效(statute of limitations)的課稅年度所釋放的準備金。若排除一次性利益,我們2013年第三季所得稅費用將約高出2,600萬美元,而2012年第三季所得稅費用將約高出3,500萬美元。
Our net income was $157 million, or $3.99 per share, compared with $183 million, or $4.46 per share, for the third quarter of 2012, and $159 million, or $3.90 per share, for the second quarter of 2013. Excluding the one-time tax benefits, our third-quarter 2013 net income would've been $131 million, or $3.32 per share, and our third-quarter 2012 net income would've been $148 million, or $3.61 per share.
我們的淨利為1.57億美元,或每股3.99美元,相較於2012年第三季的1.83億美元(每股4.46美元),以及2013年第二季的1.59億美元(每股3.90美元)。若排除一次性稅務利益,我們2013年第三季的淨利本應為1.31億美元(每股3.32美元),而2012年第三季的淨利本應為1.48億美元(每股3.61美元)。
Now, moving to cash flows, we ended the third quarter with cash and investments of $2.5 billion, down $495 million compared with June 30, 2013. The decrease was driven by $694 million used to repurchase our common stock and $34 million of capital and IP acquisitions, partially offset by $204 million in cash flow generated from operations.
接著談現金流,我們在第三季末的現金與投資為25億美元,較2013年6月30日減少4.95億美元。這一下降主要來自用於回購普通股的6.94億美元,以及資本與智慧財產(IP)收購的3,400萬美元,部分被營運所產生的2.04億美元現金流所抵銷。
During the third quarter, we bought back approximately 1.74 million shares at an average price of $399 per share. We ended the quarter with approximately $1 billion authorized by the Board for future share buybacks.
第三季期間,我們以每股平均399美元回購約174萬股。季末董事會仍核准約10億美元額度,用於未來股票回購。
And with that, I'd like to turn it over to Aleks, who will go over our sales, marketing, and clinical highlights.
接下來,我想把時間交給Aleks,他將說明我們的銷售、行銷與臨床重點。
Aleks Cukic - VP Strategy
Aleks Cukic - VP Strategy
Thank you Marshall. During the third quarter, we sold 101 da Vinci systems, 65 in the United States, 17 into Europe and 19 in rest-of-world markets. As part of the 101 system sales, five standard da Vinci systems and 24 da Vinci S systems were traded in for credit against sales for new da Vinci Si Systems. We finished the quarter with a net 72 system additions to the installed base, bringing to 2871 the cumulative number of da Vinci systems worldwide, 2042 in the US, 455 in Europe, and 374 in rest-of-world markets. 48 of the 101 systems installed during the quarter represented repeat system sales to existing customers. In total, 100 of the 101 systems sold represented da Vinci Si or Si-e systems, which included 32 dual consoles. The 36 system sales internationally included 13 into Japan and six into France.
謝謝你,Marshall。第三季我們共售出101套da Vinci系統,其中65套在美國、17套銷往歐洲、19套銷往世界其他市場。在這101套系統銷售中,有5套標準da Vinci系統與24套da Vinci S系統以折抵方式換購新的da Vinci Si系統。本季我們的裝機基礎淨增加72套,使全球da Vinci系統累計達2,871套,其中美國2,042套、歐洲455套、世界其他市場374套。本季安裝的101套系統中,有48套為既有客戶的再次購買。總計而言,售出的101套系統中有100套為da Vinci Si或Si-e系統,其中包含32套雙控制台。國際市場的36套系統銷售中,包括銷往日本13套與法國6套。
Clinically, Q3 year-over-year procedure growth was approximately 16%, which was led by the category of general surgery and paved by cholecystectomy, followed by colon-rectal resections and bariatric procedures. Our US urology business was stable, while growth in the international urology business was solid. As expected, the growth rate in the US for the nine dVH was slightly down from Q2, which continued to place pressure on US system sales.
在臨床方面,第三季手術量年增約16%,主要由一般外科帶動,其中以膽囊切除術為先,接著是結直腸切除與減重手術。我們在美國的泌尿科業務維持穩定,而國際泌尿科業務成長強勁。如預期,美國九項dVH的成長率較第二季略為下滑,持續對美國系統銷售造成壓力。
Demand for recently released new products continues to be strong. Through Q3 2013, we sold Single-Site instrument accessory kits to approximately 825 US customers. Our vessels dealer product utilization trend continues to strengthen, with most of interest coming from the specialties of colorectal, advanced general and GYN surgery. The customer adoption for both da Vinci simulator and Firefly continues to expand with 63 customers purchasing a da Vinci simulator and 48 customers purchasing Firefly systems as part of their initial system purchases this quarter.
近期推出的新產品需求仍然強勁。截至2013年第三季,我們已向約825家美國客戶銷售Single-Site器械配件套組。我們的血管封合器產品使用趨勢持續增強,主要興趣來自結直腸、進階一般外科與婦科(GYN)手術等專科。客戶對da Vinci模擬器與Firefly的採用持續擴大,本季有63家客戶購買da Vinci模擬器,另有48家客戶在其初次系統採購中一併購買Firefly系統。
In addition, we've expanded our phased rollout of both the da Vinci surgical stapling system and Single-Site hysterectomy products to several new sites. These rollouts will be extended in a measured fashion, so we do not expect them to contribute materially in the near term.
此外,我們已將da Vinci手術縫合釘系統與Single-Site子宮切除產品的分階段推廣擴展至數個新據點。這些推廣將以審慎方式逐步延伸,因此我們預期短期內不會對業績做出重大貢獻。
During the quarter, several hundred robotic abstracts and papers representing a variety of surgical specialties were published within peer reviewed journals, many focused specifically on safety and/or efficacy. Clinical conferences also produced several wide da Vinci procedure transmissions, postgraduate robotic courses, podium presentations, and clinical poster sessions, several with emphasis on safety and/or efficacy.
本季有數百篇涵蓋多種外科專科的機器人手術摘要與論文發表於同儕審查期刊,其中許多特別聚焦於安全性及/或有效性。臨床研討會也進行了多場da Vinci手術的廣泛轉播、研究所後機器人課程、口頭報告與臨床海報展示,其中多場同樣強調安全性及/或有效性。
I'll take a moment to summarize with you. Da Vinci hysterectomy is the single largest procedure that our customers perform. It is widely accepted that, when compared to open hysterectomy, the benefits provided to a patient through an MIS approach are significant. As the data supports, the rapid conversion to open hysterectomy to a minimally invasive approach continues to be led by da Vinci's incorporation into GYN practices.
我花點時間為各位做個總結。da Vinci子宮切除術是我們客戶執行量最大的單一手術項目。普遍認為,與開腹子宮切除相比,採用微創手術(MIS)方式能為病患帶來顯著益處。如數據所示,從開腹子宮切除快速轉向微創方式的趨勢,持續由da Vinci在婦科(GYN)臨床中的導入所帶動。
In a recent edition of the Journal of the Society of Laparoscopic Surgery, a group out of the Department of Obstetrics and Gynecology at Yale University published a study entitled "Robotic Versus Abdominal Hysterectomy in Women With Very Large Uteri". The study compared the results of 60 hysterectomies, 30 abdominal and 30 DVHs in patients with uteri greater than 1000 grams in weight.
在《腹腔鏡外科學會期刊》(Journal of the Society of Laparoscopic Surgery)近期一期中,耶魯大學婦產科系的一個團隊發表了一項題為「巨大子宮女性之機器人手術與腹式子宮切除之比較」("Robotic Versus Abdominal Hysterectomy in Women With Very Large Uteri")的研究。該研究比較了60例子宮切除的結果,其中30例為腹式手術、30例為dVH,患者子宮重量皆大於1,000公克。
It is generally understood that the larger the uterus, the more complex the surgery, often necessitating an abdominal hysterectomy. On a statistical scale, uteri in excess of 1000 grams are considered very large. The uteri in both cohorts studied ranged in size from between 1000 to just over 3500 grams.
一般認為,子宮越大,手術越複雜,往往需要進行腹式子宮切除。在統計尺度上,超過1,000公克的子宮被視為非常巨大。研究中兩組的子宮大小介於1,000公克至略高於3,500公克之間。
The published results were as follows. Median length of hospitalization for patients in the da Vinci cohort was one day, with a range from one to two days, as compared to 2.5 days with a range from two to nine days for patients in the abdominal cohort. Estimated blood loss was 150 milliliters for the da Vinci patient versus 425 milliliters through the abdominal approach. Transfusion rates for the da Vinci cohort was 3.3% versus 13.3% with the abdominal approach. Conversion rates from da Vinci hysterectomy to an abdominal surgery was zero, as was the hernia rate.
發表的結果如下。da Vinci組患者的住院天數中位數為1天,範圍為1至2天;相較之下,腹式組患者為2.5天,範圍為2至9天。估計失血量方面,da Vinci組為150毫升,而腹式手術為425毫升。輸血率方面,da Vinci組為3.3%,腹式手術為13.3%。da Vinci子宮切除轉為腹式手術的轉換率為零,疝氣發生率亦為零。
In their commentary, the authors pointed out the following findings. First, hysterectomies for very large uteri are challenging procedures. Second, obesity and morbid obesity and/or previous surgeries compound the difficulty. Despite these challenges, patients who are obese experience some of the greatest differential benefits for minimally invasive surgery. Finally, morbid obesity and/or previous procedures appear to not be an impediment for completing these procedures robotically.
在其評論中,作者指出以下發現。第一,針對非常巨大子宮的子宮切除屬於具挑戰性的手術。第二,肥胖、病態性肥胖及/或既往手術史會加劇手術難度。儘管存在這些挑戰,肥胖患者往往能從微創手術中獲得更顯著的相對益處。最後,病態性肥胖及/或既往手術似乎並不會妨礙以機器人方式完成這些手術。
Within general surgery, procedures related to the colon and rectal disease management have been among our most promising. Right and left colon resections, sigmoid resections, low anterior resections and rectopexy continue to exhibit solid growth.
在一般外科領域中,與結腸與直腸疾病管理相關的手術一直是我們最具前景的項目之一。右半結腸切除、左半結腸切除、乙狀結腸切除、低位前切除以及直腸固定術(rectopexy)持續展現穩健成長。
With the exception of right-handed colectomy and rectopexy, laparoscopic penetration has been modest within colorectal surgery. Rectopexy is a procedure designed to address pelvic floor disorders, or PFDs. Among other things, PFDs obstruct a patient's ability to defecate. A recent French study compared the results of patients undergoing a laparoscopic rectopexy versus a da Vinci rectopexy. 118 patients were evaluated in the study, 44 da Vinci as compared to 74 lap. The study evaluated OR time, blood loss, complications, length of hospitalization, and postoperative ODS scores for obstructive defecation syndrome.
除右側結腸切除與直腸固定術外,腹腔鏡在結直腸手術中的滲透率一直相對有限。直腸固定術是一種用於處理骨盆底功能障礙(PFDs)的手術。在其他影響之外,PFDs會阻礙患者排便能力。近期一項法國研究比較了接受腹腔鏡直腸固定術與da Vinci直腸固定術患者的結果。研究共評估118名患者,其中44名為da Vinci、74名為腹腔鏡(lap)。研究評估了手術室(OR)時間、失血量、併發症、住院天數,以及針對阻塞性排便症候群(ODS)的術後ODS評分。
Regarding total OR time, which included system time, the da Vinci rectopexy took approximately 15% longer than the laparoscopic approach, but the authors noted that their times came down over their last 20 patients and were expected to continue to trend up. Blood loss was difficult to even detect during the da Vinci rectopexy and measured only 8 milliliters as compared to 42 milliliters in the lap cohort. Complications with the da Vinci approach were 2% as compared to 11% in the lap patients. Hospitalization was reduced by a full day when using da Vinci, which the authors attributed to a less strenuous tissue manipulation due to improved vision and dexterity. Post-op ODS scores improved for patients in both groups. However, the difference in improvement for patients in the da Vinci cohort was substantial and deemed statistically significant.
就總手術室(OR)時間而言(包含系統時間),達文西直腸固定術約比腹腔鏡方式多花約15%的時間,但作者指出,在最後20位病患中,他們的手術時間已有所縮短,且預期未來仍將持續呈現上升趨勢。在達文西直腸固定術中,出血量幾乎難以察覺,僅量測到8毫升,相較之下腹腔鏡組為42毫升。達文西方式的併發症發生率為2%,相較於腹腔鏡病患的11%。使用達文西可使住院天數縮短整整一天,作者將此歸因於視野與靈活度提升,使組織操作較不費力。兩組病患的術後ODS分數皆有改善。然而,達文西組病患的改善幅度相當顯著,且被認定具有統計顯著性。
In their conclusions, the authors stated, and I quote, "Although not a randomized comparison, this study shows that ventral mesh rectopexy performed by a robot was followed by better function than lap rectopexy."
在結論中,作者表示(我引用原文):「雖然並非隨機比較,本研究顯示,以機器人進行的腹側網片直腸固定術,其功能結果優於腹腔鏡直腸固定術。」
Da Vinci thoracic procedures, specifically lobectomy and segmental resections had been steadily expanding over the past few years. Similar to colon and rectal surgery, the presence of minimally invasive resection has been minor as compared to open surgery.
達文西胸腔手術,特別是肺葉切除與肺段切除,在過去幾年持續擴展。與結腸與直腸手術類似,相較於開放手術,微創切除的占比仍然偏小。
In the recent edition of analysts of the Annals of Thoracic Surgery, physician and healthcare economists from both Harvard Medical School and Cornell Medical Center collaborated on the study which compared open surgery, video assisted thoracoscopy, or VATs, and da Vinci resections. The study evaluated the results of over 33,000 patients who had received pulmonary resection within the eight-state study cohort. While the mix of patients was dominated by patients undergoing an open resection, the rate of growth for da Vinci surgery was significant over the three-year study period. Da Vinci expanded from 0.2 of the pulmonary resection studied in the first year to 3.4 by the third year, numbering 430 in total. Da Vinci procedures were performed in all states studied with 38 being performed in community hospitals.
在近期一期《Annals of Thoracic Surgery》的分析文章中,來自哈佛醫學院與康乃爾醫學中心的醫師與醫療經濟學者合作進行研究,比較開放手術、影像輔助胸腔鏡(video assisted thoracoscopy,VATs)以及達文西切除術。該研究評估了八州研究隊列中超過33,000名接受肺部切除的病患結果。雖然病患組成以接受開放切除者為主,但在三年研究期間,達文西手術的成長率相當顯著。達文西在第一年占所研究肺部切除的0.2,至第三年增至3.4,總數為430例。研究涵蓋的所有州皆有進行達文西手術,其中有38例是在社區醫院完成。
The results. In a propensity matched analysis, da Vinci resections were associated with significant reductions in mortality, 0.2% versus 2.0% for open surgery. Length of stay was 5.9 days for the da Vinci patients versus 8.2 days for the open surgery. Overall complication rate was 43.8% for da Vinci versus 54.1% for open surgery. These improvements were all considered statistically significant.
研究結果。在傾向分數配對分析中,達文西切除術與顯著較低的死亡率相關:0.2%,相較於開放手術的2.0%。住院天數方面,達文西病患為5.9天,開放手術為8.2天。整體併發症率方面,達文西為43.8%,開放手術為54.1%。上述改善皆被視為具有統計顯著性。
In a propensity matched analysis versus VATs, da Vinci lobectomy demonstrated directional improvements in mortality and length of stay. In their summary, the authors wrote, and I quote, "Case volume for pulmonary resections have increased significantly during the study period of thoracic surgeons, and thoracic surgeons have been able to adopt the robotic approach safely. Robotic resection appears to be an appropriate alternative to VATs and is associated with improved outcomes compared with open thoracotomy."
在與VATs進行的傾向分數配對分析中,達文西肺葉切除在死亡率與住院天數方面呈現方向性的改善。在摘要中,作者寫道(我引用原文):「在胸腔外科醫師的研究期間內,肺部切除的病例量顯著增加,而胸腔外科醫師也能安全地採用機器人方式。機器人切除似乎是VATs的適當替代方案,且相較於開放胸廓切開術,與更佳的臨床結果相關。」
This concludes my remarks, and I will now turn the time over to Calvin.
以上是我的發言,接下來我把時間交給Calvin。
Calvin Darling - Senior Director of Finance
Calvin Darling - Senior Director of Finance
Thank you Aleks. I will be providing you with an update our financial forecast for 2013 on a GAAP basis. I will also provide estimates of significant non-cash expenses.
謝謝你,Aleks。我將向各位更新我們以GAAP基礎編製的2013年財務預測。我也會提供重大非現金費用的估計。
Starting with procedures, on our last call, we projected our full-year 2013 procedures to grow between 15% and 18% above the base of approximately 450,000 procedures performed in 2012. Now, with one quarter remaining in 2013, we are refining our estimate for full-year 2013 procedure growth to a range of between 16% and 17%.
先從手術量談起。在上次電話會議中,我們預估2013年全年手術量將較2012年約45萬例的基期成長15%至18%。現在,2013年僅剩一個季度,我們將2013年全年手術量成長的估計範圍精煉為16%至17%。
Moving to revenues. As has been discussed earlier, several factors are pressuring our business, making it difficult to predict system sales volumes. On our last call, we projected full-year 2013 revenue to range from approximately flat to 7% growth. We now expect full-year revenue growth in the lower half of that range.
接著談營收。如先前所討論,有數項因素正對我們的業務造成壓力,使系統銷售量難以預測。在上次電話會議中,我們預估2013年全年營收約為持平至成長7%。我們目前預期全年營收成長將落在該區間的下半部。
Turning to operating income, on our last call, we forecast operating income to fall within a range of between 37% and 38% of net revenue. We are taking steps to scale back our expenses while not compromising our longer-term expansion strategies. We continue to anticipate full-year 2013 operating income to fall within a range of between 37% and 38% of revenue.
再談營業利益。上次電話會議中,我們預測營業利益將落在淨營收的37%至38%區間。我們正採取措施縮減費用,同時不影響我們較長期的擴張策略。我們仍預期2013年全年營業利益將落在營收的37%至38%區間。
Now, with regard to non-cash stock compensation expenses, we're refining our forecast to between $169 million and $172 million for the year. We expect Other Income, which is comprised mostly of interest income, to total between $16 million and $17 million in 2013.
至於非現金的股票酬勞費用,我們將年度預測精煉為1.69億至1.72億美元。我們預期2013年的其他收入(主要由利息收入構成)合計將介於1,600萬至1,700萬美元。
With regard to income tax, as Marshall described, our Q3 tax rate benefited from nonrecurring discrete events. For Q4 2013, we'd expect our tax rate to be approximately 28% of pretax income, slightly lower than previously forecast primarily due to the geographic mix of our pretax income.
關於所得稅,如Marshall所述,我們第三季的稅率受惠於一次性的離散事件。對於2013年第四季,我們預期稅率約為稅前所得的28%,較先前預測略低,主要是因為稅前所得的地理分布組合所致。
Our share count for calculating EPS in Q3 2013 was approximately 39.3 million shares, declining 1.5 million shares in the quarter primarily due to buyback activities. In Q4, we expect our share count to decline approximately 600,000 shares further based upon the full-quarter impact of our Q3 buybacks. The actual Q4 share count will depend on several factors, including the magnitude and timing of additional share buybacks, if any.
2013年第三季用於計算EPS的股數約為3,930萬股,該季度減少150萬股,主要由庫藏股回購活動所致。在第四季,我們預期在第三季回購的整季影響下,股數將再減少約60萬股。實際第四季股數將取決於多項因素,包括是否有額外股票回購,以及其規模與時點。
That concludes our prepared remarks. We will now open the call to your questions.
以上為我們事先準備的發言。接下來我們將開放提問。
Operator
Operator
(Operator Instructions). Tycho Peterson, JPMorgan.
(接線員指示)。Tycho Peterson,摩根大通(JPMorgan)。
Tycho Peterson - Analyst
Tycho Peterson - Analyst
Hi, thanks for taking my question. I guess, first of all, just given the change in procedures in [NAC] SRT, could you talk about whether we should be assuming that there will be US placements only if system utilization continues to increase sequentially? And how are you thinking about where system utilization could ultimately go in the next couple of years?
嗨,謝謝讓我提問。我想首先,考量到[NAC] SRT手術量的變化,你們能否談談:我們是否應假設只有在系統使用率持續逐季上升的情況下,才會有美國的裝機?另外,你們如何看待未來幾年系統使用率最終可能達到的水準?
Gary Guthart - President, CEO, Director
Gary Guthart - President, CEO, Director
I think, in the near term the factors that place new systems will be a few, as you know. So one of them is procedure growth. One of them is access to new technologies for folks who have older technology. And then the last one is point of care where, in the hospital, they want to use the devices. And by far the biggest driver of those three is the procedure side.
我認為,短期內促成新系統裝機的因素會有幾項,如你所知。其中之一是手術量成長。其中之一是讓使用較舊技術的客戶取得新技術。最後一項是照護點(point of care),也就是在醫院內他們希望在哪裡使用這些設備。而在這三者之中,最主要的驅動因素無疑是手術量。
So I think utilization, over time, I think people are going to look at it and look as capital owners to drive it up. It can be lumpy though. I don't know that it has to progress linearly in terms of increases. As I said before, if you have an S platform and you want to have access to stapling, that requires and Si that can make changes as we go through.
所以我認為,隨著時間推移,人們會從資本擁有者的角度來看待使用率,並推動其提升。不過它可能會呈現不均勻的波動。我不確定它是否必須以線性的方式逐步增加。如我之前所說,如果你有一個S平台並希望能使用縫合器(stapling),那就需要Si,這樣我們才能在推進過程中做出調整。
Tycho Peterson - Analyst
Tycho Peterson - Analyst
And then on Japan, given that you're not likely to have reimbursement for additional procedures until 2016, could you maybe talk about how you think about the trends there? Is there going to kind of a pause in investments beyond this initial round of placements (technical difficulty) procedures?
接著談日本,鑑於你們在 2016 年之前不太可能就額外的手術獲得給付,你能否談談你們如何看待那邊的趨勢?在這一輪初期的裝機(技術性問題)手術之後,投資是否會出現某種暫停?
Gary Guthart - President, CEO, Director
Gary Guthart - President, CEO, Director
I think, in terms of the process for reimbursement, just so everybody knows, that will be a set of clinical data collection that is going on out there. And that will involve some hospitals getting limited approval from the government to collect that data. So we'll see that.
我想,就給付的流程而言,讓大家都知道,這將是在當地進行的一套臨床資料蒐集。而這會涉及一些醫院從政府取得有限度的核准來蒐集那些資料。所以我們會看到那樣的進展。
I think that capital sales by the broad market will be really lumpy in this period. I think it will be very hard to predict accurately what the sales profile will look like as people go through that set of clinical data and trial data. I think the commentary from the Japanese market as to their interest is strong.
我認為,在這段期間,整體市場的資本設備銷售會非常不均勻、起伏很大。當大家經歷那一套臨床資料與試驗資料的過程時,我認為將很難精準預測銷售曲線會長什麼樣子。我認為日本市場對其興趣的回饋是強勁的。
Tycho Peterson - Analyst
Tycho Peterson - Analyst
Okay. And one last one for Marshall, quickly on inventories. $200 million. Can you comment on why they were that high?
好的。最後一題給 Marshall,快速問一下庫存。2 億美元。你能評論一下為什麼會那麼高嗎?
Marshall Mohr - SVP, CFO
Marshall Mohr - SVP, CFO
We run leadtimes that we provide to our suppliers, and for particularly the system itself. And we obviously didn't sell the number of systems we had anticipated until (technical difficulty) we are still taking that inventory in. We don't think there's any exposure there. We're talking about Si, and Si is a very capable unit and capable of doing all of the surgeries we see in our near-term future.
我們會提供給供應商我們的交期(lead times),尤其是系統本身。而很明顯地,我們並沒有賣出原先預期的系統數量,直到(技術性問題)我們仍在持續接收那批庫存。我們不認為那裡有任何曝險。我們談的是 Si,而 Si 是一個非常有能力的機型,足以應付我們在可預見的短期未來所看到的所有手術。
Tycho Peterson - Analyst
Tycho Peterson - Analyst
Okay, thank you.
好的,謝謝。
Operator
Operator
Ben Andrew, William Blair.
Ben Andrew,William Blair。
Ben Andrew - Analyst
Ben Andrew - Analyst
Good afternoon. Maybe, Gary, talk a little bit about any shift in the spending plans that Calvin referred to, and if you can give us a little of the detail on that and over what time frame we might see that pull back.
下午好。Gary,或許你可以談談 Calvin 提到的支出計畫是否有任何轉變;如果可以的話,請提供一些細節,以及我們可能在什麼時間範圍內看到那樣的縮減。
Gary Guthart - President, CEO, Director
Gary Guthart - President, CEO, Director
I think there are some things that make sense in the next quarter or two in terms of spending, some things that just scale with production volume and things like that that make a lot of sense.
我認為在接下來一到兩個季度,在支出方面有些事情是合理的;有些事情會隨著產量規模而變動,諸如此類,這些都很合理。
The other side is being careful in prioritizing the investments that we make, both in terms of prototype spending and in terms of expansion plans. We have a pretty clear set of priorities in terms of the kinds of products and the markets we want to invest in. We will not short those. But for things that are perhaps a little further out or a little bit more on the edges, then we will be careful about where we put our investment.
另一方面,是在我們所做的投資上更謹慎地排定優先順序,包含原型開發支出以及擴張計畫。就我們想投資的產品類型與市場而言,我們有一套相當清楚的優先順序。我們不會在那些方面縮手。但對於可能更長期、或更偏邊緣的事項,我們會更謹慎地決定把投資放在哪裡。
Ben Andrew - Analyst
Ben Andrew - Analyst
Okay. And then on the clinical side, what sort of role do you have in data collection for things like complications and other clinical data sets relative to procedures like COLI where there's an opportunity to maybe transform a space further with a strong registry set, or clinical study? And is that a material kind of investment for you all at this point?
好的。接著在臨床面,你們在併發症等資料蒐集、以及其他臨床資料集方面扮演什麼角色?相對於像 COLI 這類手術,若能建立強而有力的登錄資料庫或臨床研究,可能有機會進一步改變該領域。而在目前這個時間點,這對你們而言是否屬於重大的投資?
Gary Guthart - President, CEO, Director
Gary Guthart - President, CEO, Director
We do have programs where we invest in clinical research. We also invest in things like supporting registries. Also, we will go out and provide materials and access to training and other types of resources to allow people to design trials. So, we perform that way.
我們確實有一些計畫會投資於臨床研究。我們也會投資於支援登錄資料庫(registry)之類的事情。此外,我們也會提供材料、訓練的管道與其他類型的資源,讓大家能夠設計試驗。所以我們會以這種方式來進行。
We also fund fellowship training. We also fund residency training in different places. So we have a set of things that we do.
我們也資助 fellowship 的訓練。我們也在不同地點資助住院醫師(residency)訓練。所以我們有一整套我們在做的事情。
There are institutions that will look for our help, and there are institutions who want to do things at arm's length and that makes sense too. So there's a combination of all of those things.
有些機構會尋求我們的協助,也有些機構希望與我們保持一定距離來做事,這也合理。所以這些做法是並存的。
I think the areas of study are diverse from very large population studies that occur in more mature procedures to smaller cohorts that are direct comparisons across one or two centers for things that are emerging. So, as you think about cholecystectomy and use of Single-Site and things like Firefly imaging, you'll see the smaller cohort studies start and those will get bigger as time goes on.
我認為研究領域相當多元,從在較成熟手術中進行的非常大型族群研究,到針對新興項目、在一到兩個中心之間做直接比較的小型隊列研究都有。因此,當你思考膽囊切除術(cholecystectomy)、Single-Site 的使用,以及像 Firefly 影像這類技術時,你會看到小型隊列研究先開始,並且隨著時間推進而逐步擴大。
Ben Andrew - Analyst
Ben Andrew - Analyst
Okay. And then finally for me, in terms of the pipeline for system sales in the quarter, did you see a shift in terms of how people characterize them as a delay or cancellation or any other trends there? Thank you.
好的。最後一題,就本季系統銷售的管線而言,你們是否看到人們對其性質的描述有所轉變,例如延後或取消,或其他任何趨勢?謝謝。
Gary Guthart - President, CEO, Director
Gary Guthart - President, CEO, Director
It's pretty similar to last quarter. We had a number of systems where we got the approvals that we were accustomed to, but then, at the end, we couldn't get the CEO or the CFO and there was a hesitation there on the basis of their own concerns or uncertainties, I should say, their own uncertainties around spending capital. And then of course there's some capital spending that's required under the ACA for IT and so forth, and so I think those are also capturing a greater part of the pie than we're used to. But I don't know that there was anything in particular I would point out.
和上一季相當類似。我們有一些系統已取得我們習慣看到的核准,但到了最後,我們無法找到 CEO 或 CFO,於是基於他們自身的疑慮或不確定性——我應該說,是他們對資本支出的不確定性——而出現猶豫。當然,ACA 之下也需要一些資本支出用於 IT 等等,所以我認為那些也正在占用比我們以往習慣更大的一部分預算。但我不覺得有什麼特別值得我指出的。
Operator
Operator
Tao Levy, Wedbush.
Tao Levy,Wedbush。
Tao Levy - Analyst
Tao Levy - Analyst
Good afternoon. So one of the questions I had was just jumping on what Ben had just asked. Is there anything that you are doing differently now on the activities or investments that you weren't doing previously, just to address some of the challenges that have cropped up over the last few quarters?
下午好。我其中一個問題是延續 Ben 剛剛問的。為了因應過去幾季浮現的一些挑戰,在活動或投資上,你們現在是否有做任何以前沒有做的不同作法?
Gary Guthart - President, CEO, Director
Gary Guthart - President, CEO, Director
No, I think the things that are perhaps front and center is making sure that people have access to all the data that's out there. There's an enormous amount of published literature on da Vinci. People looking for proof points can absolutely find them. I think the total publication database now is greater than 5000 peer-reviewed journal articles on da Vinci. The number of level II evidence and above, high-level evidence, is greater than 200.
沒有,我認為目前最核心的是確保大家能取得所有現有的資料。關於 da Vinci 已有大量已發表的文獻。想找佐證的人絕對找得到。我想目前整體的發表資料庫已超過 5000 篇關於 da Vinci 的同儕審查期刊文章。第二級證據(level II)及以上的高等級證據文章數量已超過 200 篇。
The issue is not a dearth of clinical data. There were cost studies. We'll be posting them on -- links to them on the Web. There's a fair amount out there.
問題不在於缺乏臨床資料。也有成本研究。我們會在網站上張貼——提供連結。外部已有相當多資料。
What we can do better is make sure people know it and see it and are able to digest it. So we've been doing that kind of activity.
我們可以做得更好的是,確保大家知道、看得到,並且能夠消化這些資料。所以我們一直在做這類活動。
We've talked about, both in Japan and in Europe, the economic analysis that needs to be done with regard to reimbursement from government payors is work that we can do, and we are having success in that work. The data is out there. The analysis can be done. And so we are making those kinds of investments. And so we've been scaling.
我們談過,無論在日本或歐洲,針對政府支付方的給付所需進行的經濟分析,是我們可以做、而且我們在這方面也取得成果的工作。資料都在那裡。分析也可以完成。因此我們正在進行這類投資。所以我們一直在擴大規模。
Tao Levy - Analyst
Tao Levy - Analyst
Okay. And if you can maybe comment on sort of how we should think about prices on per procedure over the near term until I guess systems start to recover. Is it here sort of in the $1850, $1860 range?
好的。另外,你能否評論一下,在短期內、直到我想系統銷售開始回升之前,我們應該如何看待每例手術的價格?是否大致落在 1850、1860 美元的區間?
Gary Guthart - President, CEO, Director
Gary Guthart - President, CEO, Director
I let Calvin go into the modeling and the mix, but before he does, just a high-level comment. I think there are a couple things going on. On things like Single-Site and some of the benign procedures that are more cost sensitive, we have offerings that reflect that greater cost sensitivity. And we are happy to provide them. I think, it makes sense and they fit the procedure profile.
我讓 Calvin 來談模型與組合(mix),但在他之前,我先做個高層次的評論。我認為有幾件事正在同時發生。像 Single-Site 以及一些對成本更敏感的良性手術,我們有相應的產品方案來反映那種更高的成本敏感度。而我們也很樂意提供。我認為這是合理的,而且它們符合該手術的特性。
And at the other end, on the more complex procedures, the cancers, some of more reconstructive procedures, we have a set of products that have -- carry higher ASPs, the stapler and vessel sealer and the like. And so I'll let Calvin go through the modeling dynamics for you, but those are the push and pull of this kind of conversation.
而在另一端、也就是較複雜的手術流程、癌症手術以及一些較具重建性的手術,我們有一系列產品——其平均售價(ASP)較高,例如吻合器、血管封合器等。所以我會讓 Calvin 為你說明建模的動態,但這些就是這類對話中的拉鋸因素。
Calvin Darling - Senior Director of Finance
Calvin Darling - Senior Director of Finance
And as Marshall described on the call, the Q3, the lower revenue per procedure in Q3 specifically was driven by lower stocking orders associated with the lower system sales in Q3. As well as timing of orders, we saw hospitals reducing inventory levels in the quarter as well.
正如 Marshall 在電話會議中所描述的,第三季(Q3)每例手術收入較低,特別是因為第三季系統銷售較低,導致與之相關的備貨訂單較少所致。此外也有訂單時點的因素,我們也看到醫院在該季度降低了庫存水位。
Longer-term, as Gary was mentioning, the initial sales of and increased utilization of vessel sealer product, Firefly and stapler, will help us garner a larger portion of the overall procedure revenue and serve to bolster our revenue per procedure. But then offsetting that will be diminishing impact of stocking orders as well as procedure mix as we move deeper into benign procedures and they become a larger portion of our overall business. It's likely, in the much longer term, that this procedure mix could serve to trend the overall revenue per procedure down.
從較長期來看,如 Gary 提到的,血管封合器產品、Firefly 與吻合器的初期銷售與使用量提升,將有助於我們取得整體手術收入中更大的一部分,並支撐我們的每例手術收入。但與此同時,隨著我們更深入良性手術領域、且其占我們整體業務的比重提高,備貨訂單的影響將逐步減弱,手術組合也會帶來抵銷效果。在更長期來看,這種手術組合可能會使整體每例手術收入呈現下行趨勢。
Tao Levy - Analyst
Tao Levy - Analyst
So should we keep it in sort of this $1860 level or higher? I wasn't sure which --
所以我們應該把它維持在大約 1,860 美元這個水準或更高嗎?我不確定是哪一個——
Marshall Mohr - SVP, CFO
Marshall Mohr - SVP, CFO
Yes, there are a lot of factors. I think there were some specific factors that impacted Q3 that will be pretty relevant --
是的,影響因素很多。我認為有一些特定因素影響了第三季(Q3),而這些因素在——會相當相關——
Tao Levy - Analyst
Tao Levy - Analyst
Higher than that.
比那個更高。
Marshall Mohr - SVP, CFO
Marshall Mohr - SVP, CFO
-- as you look at Q4 and next year and some of these other things are longer-term.
——當你看第四季(Q4)和明年時;而其他一些因素則是更長期的。
Tao Levy - Analyst
Tao Levy - Analyst
If I could ask the last question. Procedure trends in the quarter, it seems like September might have been particularly strong for you guys on a worldwide basis. Is that the case? Or September year-over-year was pretty much the same?
如果我可以問最後一個問題。本季度的手術趨勢,看起來 9 月在全球範圍內對你們而言可能特別強勁。是這樣嗎?還是 9 月的年增率其實差不多?
Gary Guthart - President, CEO, Director
Gary Guthart - President, CEO, Director
Generally speaking, you see people coming back from vacations globally in September, and so the seasonality there is such that September is usually stronger than the prior months. And we would expect that.
一般來說,全球在 9 月大家會從假期回來,因此季節性因素使得 9 月通常會比前幾個月更強。我們也預期會如此。
And then the other piece is that as our business has a greater share of benign surgeries in it over time, those tend to be more subject to seasonality. So the mix is becoming a more seasonal mix relative to prior years. And so you see both of those effects kind of compound.
另外一點是,隨著我們的業務隨時間推移在良性手術中的占比提高,這類手術通常更容易受到季節性影響。因此,相較於過去幾年,我們的組合正變得更具季節性。所以你會看到這兩種效應有點疊加在一起。
Tao Levy - Analyst
Tao Levy - Analyst
Thanks.
謝謝。
Operator
Operator
David Roman, Goldman Sachs.
David Roman,高盛。
Unidentified Participant
Unidentified Participant
Hi guys. This is Chris in for David. Can you hear me okay? Wonderful. Thank you for taking the questions.
嗨,各位。我是 Chris,代替 David。你們聽得到我嗎?太好了。謝謝你們回答問題。
First question, I feel like, historically, the mantra has always been that procedure growth drives system utilization. But at this point, it feels like the rate of change in the delta for a procedure is a lot slower than what's happening at the system level, and that's kind of given rise to this overcapacity debate a little bit.
第一個問題,我覺得從歷史上看,一直以來的口號都是「手術量成長帶動系統使用率」。但在這個時間點,感覺每例手術的變化幅度(delta)的變動速度,比系統層級正在發生的變化慢得多,這也在某種程度上引發了「產能過剩」的討論。
And I'm a little bit curious about how your visibility, and given the revised guidance, where the confidence is coming from in the revised outlook on systems growth. What has changed in the conversations with administrators for some of the pipeline accounts that makes you feel that these guys are still in the pipeline, that they won't push out their decision-making another six months, nine months or 12 months? And maybe you can share a couple of anecdotes of specific conversations that are happening to let us have a better feel for it.
我有點好奇,在你們下修指引之後,你們的可見度如何?以及對於修正後系統成長展望的信心來源是什麼。在與一些管線(pipeline)客戶的管理層對話中,有哪些改變讓你們覺得這些客戶仍在管線中,不會把決策再往後推 6 個月、9 個月或 12 個月?也許你們可以分享幾個具體對話的軼事,讓我們更有感覺。
Marshall Mohr - SVP, CFO
Marshall Mohr - SVP, CFO
I'll answer the last part first. On the systems side, I think we've given you a pretty broad range for the results for Q4. And that reflects -- Calvin even said this in his script -- that reflects uncertainty as to how capital will close. I don't think we exuded any particular confidence on what will happen in Q4 relative to Q3 on --
我先回答最後一部分。在系統方面,我想我們已經給了你們第四季(Q4)結果一個相當寬的區間。而那反映了——Calvin 甚至在他的講稿裡也說了——那反映了資本支出成交(close)的不確定性。我不認為我們對第四季相對於第三季會發生什麼,在——方面表現出任何特別的信心——
Gary Guthart - President, CEO, Director
Gary Guthart - President, CEO, Director
Our visibility to procedures is better. It is imperfect but it is better than into capital purchasing decisions, particularly in the US where you are seeing some market dynamic changes. And so we've given you a broad range, and the reason for that broad range is it's hard to predict how a hospital administration will be some of their decisions. Right now, some of the anecdotes are that hospital administrators are trying to project what their revenues will look like as the elements of the ACA get implemented. And that revenue uncertainty on their side just flows through into capital decision-making uncertainty down the line.
我們對手術量的可見度更好。它並不完美,但確實比對資本採購決策的可見度更好,特別是在美國,你會看到一些市場動態的變化。因此我們給了你們一個寬區間,而之所以是寬區間,是因為很難預測醫院管理層在某些決策上會如何行動。目前的一些例子是,醫院管理者正試圖預估在《平價醫療法案》(ACA)的各項要素逐步落實後,他們的收入會是什麼樣子。而他們那邊的收入不確定性,就會一路傳導成後續資本決策的不確定性。
Unidentified Participant
Unidentified Participant
Great, that's very helpful. Thank you. And if I can have a follow-up here, I'm curious and I know that there's a lot of work being done on the share repurchase side, but given the significant amount of cash that you guys have and the financial flexibility, is there any reason that you wouldn't be able to up the R&D spending and really focus on addressing some of the concerns that have been out in the media and some of the major bodies of recent to help address some of the perception issues that seem to kind of keep coming up and potentially could be impacting some of the near-term system placement sales? And you could -- I feel like, with the financial flexibility, that more repurchases could offset that level of spending. Is that something that is on the table or has been considered or not?
很好,這非常有幫助。謝謝。如果我可以追問,我很好奇——我知道你們在庫藏股回購方面做了很多工作——但考量你們手上有大量現金與財務彈性,有沒有任何原因使你們無法提高研發(R&D)支出,並真正聚焦於解決媒體上提出的一些疑慮,以及近期一些主要機構的關切,以協助改善那些似乎反覆出現、並可能影響短期系統裝機銷售的觀感問題?而且你們——我覺得以你們的財務彈性,更多回購可以抵銷那樣的支出水準。這是否在考量範圍內,或曾被考慮過,還是沒有?
Gary Guthart - President, CEO, Director
Gary Guthart - President, CEO, Director
With regard to -- there's a couple of things wrapped together there, just teasing them apart. With regard to the R&D spend side, we are thoughtful and serious about our R&D priorities and the spending the goes with it. We listen really carefully to surgeons and hospital customers about what we think they need and what they think they need to make for both great surgery and surgery whose economics makes sense for all of the players. And so that's baked into our product development pipeline and something we do continuously.
關於——你把幾件事包在一起了,我先把它們拆開來談。就研發支出而言,我們對研發優先順序以及相應投入是審慎且認真的。我們非常仔細地聆聽外科醫師與醫院客戶,了解我們認為他們需要什麼,以及他們認為自己需要什麼,才能同時達成優質手術,以及對所有參與者而言在經濟性上合理的手術。因此這些都已納入我們的產品開發管線中,而且是我們持續在做的事情。
With regard to R&D being the solution to some of the concerns in the press, I would encourage you to go look at our website, look at the data. The safety profile of da Vinci is outstanding when it is compared with the surgical alternatives that people have. So, I think, on that side, that's not really an R&D investment sort of issue. With regard to the use of cash and buybacks and how we think about that, I'll turn that to Marshall.
至於把研發視為解決媒體疑慮的方案,我會建議你去看我們的網站、看相關數據。當與人們可選擇的其他手術替代方案相比時,達文西(da Vinci)的安全性表現非常出色。所以我認為在那一端,這並不是一個需要靠研發投資來解決的問題。至於現金運用、回購,以及我們如何思考這些,我把這題交給 Marshall。
Marshall Mohr - SVP, CFO
Marshall Mohr - SVP, CFO
We look for opportunities or discontinuities in the share price relative to the market, and we did some buybacks this last quarter. It's really a board decision. We'll be having those discussions on an ongoing basis with the board and you will see what comes out of it.
我們會尋找股價相對於市場出現機會或不連續(discontinuities)的時點,而我們在上一季做了一些回購。這其實是董事會的決策。我們會持續與董事會進行這些討論,你們也會看到最後的結果。
Unidentified Participant
Unidentified Participant
All right, great. Very helpful. Thank you guys.
好,太好了。非常有幫助。謝謝各位。
Operator
Operator
Amit Hazan, SunTrust.
Amit Hazan,SunTrust。
Amit Hazan - Analyst
Amit Hazan - Analyst
Good afternoon guys. I thought maybe I'd ask the first question about existing versus new customers. Just regarding the US system side, if you can distinguish between existing customers adding capacity and then new customers? I think, if we think about last quarter, you seem to be saying that most of the weakness came from existing customers who chose to defer. It seems like that's the case again here. What has been happening more on the new customer side, new customer additions, and the trend line there?
各位下午好。我想我先問一個關於既有客戶與新客戶的問題。就美國系統端而言,你們能否區分一下是既有客戶擴充產能,還是新客戶導入?我想如果回想上一季,你們似乎在說大部分疲弱來自既有客戶選擇延後。這次看起來又是同樣情況。那在新客戶端——新客戶新增以及那邊的趨勢線——最近發生了什麼?
Calvin Darling - Senior Director of Finance
Calvin Darling - Senior Director of Finance
Just to kind of review the numbers, as was mentioned, there were 65 total system sales in the third quarter. 22 of them went to brand-new customers, greenfields as we call them, and 43 were to existing customers. So, then let's see. It was 19 of them -- 24 involved trade-ins, so that means 19 added systems for capacity reasons in the quarter.
只是簡單回顧一下數字,如先前提到的,第三季系統總銷售量為 65 台。其中 22 台賣給全新客戶,我們稱之為綠地(greenfields),另外 43 台賣給既有客戶。那麼,接著我們來看。其中有 19 台——有 24 台涉及以舊換新(trade-ins),也就是說本季因產能需求而新增系統的是 19 台。
So I think when you look at the capital environment, we talked about the issues impacting it. I believe the issues described, whether it be capacity from the decreasing growth in benign hysterectomy or the various macro issues, including the ACA, I think they really impacted all of these categories.
所以我認為,當你看資本環境時,我們談過影響它的問題。我相信所描述的這些問題,不論是因良性子宮切除術成長放緩而導致的產能因素,或是包含 ACA 在內的各種總體因素,我認為它們確實影響了所有這些類別。
Amit Hazan - Analyst
Amit Hazan - Analyst
Okay. Then moving onto the procedure side, I want to just make sure I ask the question so it's very clear. I think you might have touched on it. But if we go through the US benign hysterectomy side and think about how to model it for the next several quarters and how you saw this quarter versus last quarter, is the impact that you are seeing there -- and obviously I'm referring to the concerns, the developments earlier in the year more than anything -- has it gotten -- did it get worse this quarter or was it something that you saw as stable versus last quarter?
好的。接著轉到手術量這一端,我想確認我把問題問得很清楚。我想你可能已經提到一些。但如果我們看美國良性子宮切除術這一塊,思考未來幾季要如何建模,以及你們觀察本季相較上季的情況,你們在那裡看到的影響——而且我指的顯然主要是今年上半年那些疑慮與進展——是否有變得——本季是否變得更糟,還是說相較上季是穩定的?
Aleks Cukic - VP Strategy
Aleks Cukic - VP Strategy
As we mentioned in the script, I think it's following a pretty normal trajectory or trend from what we introduced in Q2 and in Q3, the Q1, Q2, Q3. So it was pretty stable, and I would say seasonally stable going into a Q3, so not much of a change between the two quarters.
如同我們在講稿中提到的,我認為它正沿著相當正常的軌跡或趨勢發展,從我們在 Q2、Q3 以及 Q1、Q2、Q3 所提出的內容來看。所以相當穩定,我會說進入 Q3 在季節性上也算穩定,因此兩個季度之間沒有太大變化。
Amit Hazan - Analyst
Amit Hazan - Analyst
Great. Just the last one for me. In terms of the impact from that same noise on other procedure categories, urology or general surgery in the US, do you feel at all that hospitals have applied more scrutiny to those as well because of the noise factor coming out of the first half of this year?
很好。我最後一個問題。就同樣那些雜音對其他手術類別的影響而言,例如美國的泌尿科或一般外科,你是否覺得醫院也因為今年上半年出現的雜音因素,而對那些類別施加了更多審視?
Aleks Cukic - VP Strategy
Aleks Cukic - VP Strategy
It's an interesting question. You really have to tease it apart and you have to take a look at the underlying condition, the surgical specialty itself, the alternative opportunity, the alternative treatment. In other words, when you're looking at urology, and you're talking about kidney cancer, bladder cancer, prostate cancer, I think it's safe to say that you are more immune to some of these sort of allegations that people are throwing out in the media than you are versus, let's say, a benign procedure that has some benign therapies and they'll pile on costs and some incorrect comparators. And so I would say the majority of that noise that we have heard and have felt is probably been on the benign GYN side more than anything else we've seen thus far. And I think that continues.
這是個有趣的問題。你確實必須把它拆開來看,並檢視其背後的病況、外科專科本身、替代方案、替代治療。換句話說,當你看泌尿科,談的是腎癌、膀胱癌、攝護腺癌時,我認為可以很有把握地說,相較於媒體上有人拋出的某些指控,你對這類指控的免疫力更強;相對地,若是良性手術,因為存在一些良性療法,他們會把成本堆上去,並使用一些不正確的比較基準。因此我會說,我們聽到並感受到的大多數雜音,迄今為止主要都集中在良性婦科(GYN)這一端,遠多於我們目前看到的其他領域。而且我認為這種情況仍在持續。
Amit Hazan - Analyst
Amit Hazan - Analyst
Okay, thanks guys.
好的,謝謝各位。
Operator
Operator
David Lewis, Morgan Stanley.
David Lewis,摩根士丹利。
Jon Demchick - Analyst
Jon Demchick - Analyst
This is actually Jon Demchick in for David. Thanks for taking the questions. I just had a quick question on I guess a few pipeline products. of you guys. Starting with Single-Site, I had a question about adding wristed capabilities. You mentioned I guess the needle driver that should be submitted for 510(k) approval next year. Are there plans to expand the wristed capabilities across other aspects of the Single-Site platform? Like what are the main obstacles in doing this? And what impact do you believe this could have on broader adoption?
其實我是代替 David 的 Jon Demchick。謝謝讓我提問。我有個簡短問題,關於我想是你們幾個產品管線(pipeline)項目。你們的。先從 Single-Site 開始,我想問關於加入可彎腕(wristed)能力。你提到明年應該會送交 510(k) 審批的持針器(needle driver)。是否有計畫把可彎腕能力擴展到 Single-Site 平台的其他面向?例如這麼做的主要障礙是什麼?你認為這對更廣泛的採用會帶來什麼影響?
Gary Guthart - President, CEO, Director
Gary Guthart - President, CEO, Director
I think -- so the first question is it limited to needle driver or can it be taken more broadly? I think that a needle driver is clearly the first one to go with with regard to Single-Site as applied to hysterectomy. I think that once you have that architecture, you can start to broaden it in terms of what's possible. And the decisions that would be made as to which ones come next and why will have a lot to do with which indications are the next most interesting indications for Single-Site. So that will be a process. If you've followed us for a while, you'll see that same kind of behavior that, as indications change, then you bring instruments in to help you optimize that set of indications.
我想——所以第一個問題是,它是否僅限於持針器,或是可以更廣泛地延伸?我認為就 Single-Site 應用於子宮切除術而言,持針器顯然是第一個要導入的。我認為一旦你有了那個架構,就可以開始在可行性上擴展。至於接下來要做哪些、以及為什麼要做,將很大程度取決於 Single-Site 下一個最有吸引力的適應症(indications)是哪些。所以那會是一個過程。如果你們追蹤我們一段時間,就會看到同樣的做法:當適應症改變時,你就會導入器械來幫助你把那組適應症最佳化。
Jon Demchick - Analyst
Jon Demchick - Analyst
And then second also I guess, moving onto the stapler rollout, as you continue with the rollout, I was just wondering if there was a potential timeline in expanding the stapler offering, the different sizes, so maybe it could be a little more effective for bariatric surgery or other surgeries.
第二個問題,我想是關於吻合器(stapler)的推廣(rollout)。隨著你們持續推廣,我想問是否有一個可能的時間表,用於擴充吻合器的產品供應、不同尺寸,讓它在減重手術(bariatric surgery)或其他手術上可能更有效。
Gary Guthart - President, CEO, Director
Gary Guthart - President, CEO, Director
So our first expansion will really be in terms of number of sites supported with the existing stapler. So the stapler we have today is really targeted and optimized for colorectal procedures in terms of how big it is and what the staple reloads look like, and so we're going to do that. And that's what we're focused on in the near term.
所以我們第一階段的擴充,主要會是在既有吻合器所支援的站點(sites)數量上。我們目前的吻合器在尺寸以及釘匣補充件(staple reloads)的設計上,確實是針對並最佳化於大腸直腸(colorectal)手術,因此我們會先做這件事。這也是我們短期內的重點。
Longer term, we are working on prototypes and developing the capability for other types of reloads focused on other types of procedures. And we'll do that. That will be further out. That's not a near-term.
較長期來看,我們正在製作原型並開發其他類型釘匣補充件的能力,聚焦於其他類型的手術。我們會去做。那會是在更後面。那不是短期內的。
Jon Demchick - Analyst
Jon Demchick - Analyst
Okay, very helpful. I just had a quick follow-up on the procedure guidance. I know you guys have given a little bit of detail here, but I just wanted to push a little further. I think it implies roughly 13% to 17% procedure growth in the fourth quarter. And I was wondering if maybe you could discuss some of the assumptions across the product categories that drove you to that guidance, and if you see any significant acceleration or deceleration across any of the large groups.
好的,很有幫助。我還有一個關於手術量指引(procedure guidance)的簡短追問。我知道你們已經提供了一些細節,但我想再追問得更深入一點。我認為這大致意味著第四季手術量成長約 13% 到 17%。我想請你們談談,促使你們給出該指引的各產品類別假設是什麼,以及你們是否看到任何大型類別出現顯著加速或減速。
Calvin Darling - Senior Director of Finance
Calvin Darling - Senior Director of Finance
Yes, I think it's probably similar to the commentary we had last quarter in that, at the higher end of the range, you're talking about a continuation of the trends that we are on from benign gynecology, general surgery, and prostatectomy in the US as well as international growth rates. At the lower end of the guidance would just be contemplation of if other factors come into play in terms of a further decline in benign demand for benign procedures. You're entering a quarter that's typically very strong seasonally, and if it comes out less strong for some reason, that would be considered as well as if you see any changing trends in cholecystectomy or prostatectomy, that would be reflective of the lower end.
是的,我想這可能和我們上季的評論類似:在區間的高端,你談的是美國良性婦科、一般外科與攝護腺切除術(prostatectomy)的趨勢延續,以及國際市場的成長率。在指引的低端,則是考量若有其他因素介入,例如良性手術的良性需求進一步下滑。你正進入一個季節性通常非常強的季度;如果因某些原因表現不如以往強勁,這也會被納入考量;另外,如果你看到膽囊切除術(cholecystectomy)或攝護腺切除術的趨勢有任何變化,也會反映在低端。
Jon Demchick - Analyst
Jon Demchick - Analyst
Thank you, very helpful.
謝謝,很有幫助。
Operator
Operator
Bob Hopkins, Bank of America.
Bob Hopkins,美國銀行。
Bob Hopkins - Analyst
Bob Hopkins - Analyst
Good afternoon. So I just wanted to ask a big picture question on procedure volume growth. As I look at the model going back to the first quarter of 2012, your procedure volume growth was close to 30%, and it's kind of gone down a little bit each quarter. And now we are at 16% this quarter, and you're looking at fourth quarter maybe being at the same level or a little bit lower. And so I guess, just from a big picture perspective, I wanted to get a sense of your confidence that the sort of midteens procedure volume growth rate is close to a bottom, or is the bottom. Any thoughts there would be helpful.
午安。我想從更宏觀的角度問一個關於手術量成長的問題。當我回頭看模型到 2012 年第一季,你們的手術量成長接近 30%,之後每一季似乎都略微下滑。而本季是 16%,你們看第四季可能在相同水準或略低。所以我想,從大方向來看,我想了解你們對於「十幾個百分點中段」的手術量成長率已接近底部、或就是底部的信心程度。任何想法都會很有幫助。
Gary Guthart - President, CEO, Director
Gary Guthart - President, CEO, Director
I don't think we are ready to give really 2014 guidance. What I would say here in terms of what are the dynamics, what's going on underneath these things, I think we have a large category that, in the US, grew quickly, and is now growing more slowly, and that was gynecology. And we have a large category in the US in general surgery that's on the early part of this adoption.
我不認為我們已準備好提供真正的 2014 年指引。就這裡我想說的是,從動態來看、這些事情底層正在發生什麼,我認為我們有一個大型品類在美國曾快速成長,現在成長放緩,而那就是婦科。而我們在美國的一般外科也有一個大型品類,正處於採用曲線的早期階段。
And I think the answer to your question is going to come down to the rates of growth on both of those sides. And I think what you would expect of the Company is to manage the activities that would support growth. And so in the US, our activities are focused on supporting general surgery growth. And that comes down to making sure the product set makes sense for that customer, making sure that our training capability is aligned and ready to go, our sales force is capable of doing what they need to do. And we have opportunity for growth or accelerated growth in OUS markets, in Japan, where we are making investments in Europe. So those are the underlying drivers. And how it shakes out in future quarters we will report to you as we have greater visibility.
我認為對你問題的回答,將歸結於這兩端的成長率。我也認為,你對公司的期待會是管理那些能支持成長的活動。因此在美國,我們的活動聚焦於支持一般外科的成長。這歸結為確保產品組合對該客戶而言合理、確保我們的訓練能力一致且已準備就緒、我們的銷售團隊具備完成其所需工作的能力。此外,我們在美國以外(OUS)市場也有成長或加速成長的機會,包括日本,以及我們正在歐洲進行投資的地方。所以這些就是底層的驅動因素。至於未來幾季會如何發展,當我們有更高的能見度時,會向各位報告。
Bob Hopkins - Analyst
Bob Hopkins - Analyst
You know, I appreciate that. I really wasn't asking about any particular quarter, just asking about all the different trends that are impacting growth and where we stand now and just trying to gauge your confidence on, at this point, are there more positives than negatives. And again, just trying to gauge confident as to sort of where we are in the cycle right now and your confidence that this obviously critically important metric to your Company, that we have your best sense as to where that is going to fall out.
你知道,我很感謝。我其實不是在問任何特定季度,只是想問所有影響成長的不同趨勢、我們目前所處的位置,並試著衡量你們的信心——就目前而言,正面因素是否多於負面因素。同樣地,只是想衡量我們現在在週期中的位置,以及你們的信心:這顯然是對貴公司極其重要的指標,我們想聽到你們最好的判斷,這最終會落在什麼樣的結果。
Aleks Cukic - VP Strategy
Aleks Cukic - VP Strategy
One of the challenges has always been trying to breeze the assumptions that we've given you and hold them for long periods of time. In other words, we are -- we're almost -- the way the question is framed, it's almost asking us to sort of freeze the assumption as the final assumptions and not take into consideration things like potential expansion of let's say Single-Site hysterectomy and/or international market growth where we are putting in a lot of resources and training centers and so on and so forth.
其中一個挑戰一直是,試著把我們提供給你們的假設「固定住」,並在很長一段時間內維持不變。換句話說,我們——我們幾乎——以這種提問方式來看,幾乎是在要求我們把這些假設凍結為最終假設,而不去考量例如單孔(Single-Site)子宮切除術的潛在擴張,和/或我們投入大量資源、訓練中心等等的國際市場成長。
So, I would say, from a confidence standpoint, we believe there are a lot of future drivers and present drivers in the business. And it becomes, as it always does, and execution story, both downstream and upstream execution of what we think are great opportunities. And that's what you should judge us on, and that's where our focus is.
所以,我會說,就信心而言,我們相信業務中有許多未來的驅動因素以及當前的驅動因素。而這也一如既往地,成為一個執行的故事——無論是下游或上游的執行,去把我們認為很棒的機會落實。這就是你們應該用來評價我們的地方,也是我們的聚焦所在。
Gary Guthart - President, CEO, Director
Gary Guthart - President, CEO, Director
Time for one more follow-up question.
再開放一個追問。
Bob Hopkins - Analyst
Bob Hopkins - Analyst
Thanks. Just one real quick one on utilization, that's also a challenging part of the model going forward. How do you think that we should be thinking about utilization sort of per system going forward? I assume that needs to continue to climb up, but just any general thoughts on kind of utilization per installed base as we look forward?
謝謝。關於使用率(utilization)我再問一個很快的問題,這也是未來模型中具挑戰的一部分。你們認為我們應該如何看待未來每套系統的使用率?我假設這需要持續上升,但想聽聽你們對於展望未來、以已安裝基礎(installed base)來看每套系統使用率的一些一般性想法。
Calvin Darling - Senior Director of Finance
Calvin Darling - Senior Director of Finance
If you look at the trends coming up prior to 2013, we've seen gradual increases in utilization per system as measured by procedures done in a quarter as a numerator and denominator of the systems installed at the beginning of the quarter. We've seen that gradually increasing.
如果你看 2013 年之前的上升趨勢,我們看到每套系統的使用率逐步增加;其衡量方式是以單季完成的手術量作為分子,分母則是該季初已安裝的系統數。我們看到這個指標逐步上升。
Now you get to 2013 with the moderating growth in benign gynecology, now you're seeing moderate decreases in each of the first three quarters of this year. Ultimately, I think we still say procedures are really what drives this business here. There are other factors that impact the timing of system sales, which we have been through. But, again, procedures and the greater growth there is going to be the key. And I think the ultimate utilization is going to depend on a lot of factors, hospitals gaining efficiency, Affordable Care Act, procedure mix, so the ultimate direction, it's hard to really say.
到了 2013 年,隨著良性婦科的成長趨於溫和,你現在看到今年前三季每一季都有溫和的下降。最終,我認為我們仍會說,手術量才是真正驅動這門生意的因素。還有其他因素會影響系統銷售的時點,而我們也經歷過。但再次強調,手術量以及其更高的成長,將會是關鍵。而我認為最終的使用率將取決於許多因素:醫院提升效率、《平價醫療法案》(Affordable Care Act)、手術組合等;因此最終方向很難真正下定論。
Bob Hopkins - Analyst
Bob Hopkins - Analyst
Thanks very much.
非常感謝。
Gary Guthart - President, CEO, Director
Gary Guthart - President, CEO, Director
That was our last question. As we've said previously, while we focus on financial metrics such as revenues, profits, and cash flow, during these conference calls, our organizational focus remains on increasing patient value by improving surgical outcomes and reducing surgical trauma.
這是我們最後一個問題。如同我們先前所說,雖然在這些電話會議中我們會聚焦於營收、獲利與現金流等財務指標,但我們組織的重點仍是透過改善手術結果並降低手術創傷,來提升病患價值。
The following is a part of an interview published by Medscape with Dr. Joseph Colella, Director of Robotic surgery at Magee Women's Hospital, part of UPMC. When he was asked about the future of robotic assisted surgery, he answered as follows. "As a potential patient, stop for a moment and put on the common sense hat. The surgeon tells you that he can see 100% better in three dimensions, that he can sew better, and in the future he'll be able to do every procedure through one incision. You can imagine that the sky is the limit in employing robotic surgery. It is an enabling technology. I firmly believe that we are finding new and beneficial applications almost on a monthly basis. For instance, nobody ever thought you would be able to resect tumors of the larynx without taking half the face of part to get to them. With a robot in the right hands, you can do those operations in an hour and the patient goes home the next day."
以下內容摘自 Medscape 發表的一段訪談,受訪者為 UPMC 旗下 Magee Women's Hospital 的機器人手術主任 Joseph Colella 醫師。當他被問到機器人輔助手術的未來時,他回答如下。「作為一名潛在病患,先停一下,戴上常識的帽子想一想。外科醫師告訴你,他能以三維方式看得好 100%,他能縫合得更好,而且未來他將能透過一個切口完成每一項手術。你可以想像,運用機器人手術的可能性是無限的。這是一項賦能技術。我堅信,我們幾乎每個月都在發現新的、有益的應用。例如,過去沒有人認為你能在不切除半張臉的一部分來接近腫瘤的情況下,切除喉部腫瘤。在合適的人手中使用機器人,你可以在一小時內完成那些手術,病患隔天就能回家。」
This concludes today's call. We thank you for your participation and support on this extraordinary journey to improve surgery, and we look forward to talking with you again in three months.
今天的電話會議到此結束。感謝各位在這段改善外科手術的非凡旅程中的參與與支持,我們期待三個月後再與各位通話。
Operator
Operator
Thank you. Ladies and gentlemen, that does conclude your conference call for today. We do thank you for your participation and for using AT&T Executive Teleconference. You may now disconnect.
謝謝。各位女士、先生,今天的電話會議至此結束。我們感謝各位的參與,以及使用 AT&T Executive Teleconference。您現在可以掛線。